2.2. Patients and recruitment
long-coronavirus disease syndrome, Raynaud disease, psoriasis, RLS, dermatological disease
ACUTE INFECTION, VIRUS, RAYNAUD DISEASE, CIRCULATORY DISORDERS, DISEASE, ATOPIC DERMATITIS, RECRUITMENT, PSORIASIS, CORONAVIRUS, HEART, SEVERE ACUTE RESPIRATORY SYNDROME, DERMATOLOGICAL DISEASE
A total of 51 patients (n = 17 in each arm) included in the trial. Patients who meet the following inclusion criteria will be included in the study: age between 18 and 75 years; diagnosis of RLS confirmed by a trained medical specialist (“Facharzt”) in accordance with the diagnostic criteria,Patients who meet any of the following criteria are excluded: indication for iron substitution therapy (exceptions are iron substitution that has already been carried out without sufficient symptom improvement or refusal of the iron substitution therapy by the patient); regular use of RLS triggering/exacerbating medications (such as mirtazapine, mianserin, clozapine, olanzapine, risperidone, haloperidol, sulpiride, promethazine); use of hydrotherapy, acupuncture, or acupressure in the last 4 weeks prior to inclusion or planned in the next 12 weeks; acute infection with severe acute respiratory syndrome coronavirus type 2 virus or presence of long-coronavirus disease syndrome; for women: pregnant or breastfeeding; presence of a serious acute and/or chronic organic or serious mental illness that does not allow participation in the study intervention (e.g., advanced cardio/pulmonary disease New York Heart Association classification/COLD III + IV); known Raynaud disease and advanced circulatory disorders of the extremities; inadequately treated dermatological disease in the therapeutic area (large wounds, severe atopic dermatitis, severe psoriasis, etc); abuse of medicines, drugs and/or alcohol; existing treatment with opioids; participation in an intervention study during the same period of the study or in the last 3 months prior to the start of the study for this condition; dependence on the study site (e.g., employee).The recruitment of study patients will be carried out primarily by advertising on public transport, newspaper advertisements, newsletters of medical institutions, the internet, flyers at general practitioners’ clinics, and neurological specialist practices. If patients meet the study criteria, they must sign an informed consent form before participating in the study or before randomization. The study physician obtains informed consent and signs a written informed consent form. The consent form contains the agreement to participate in the study, as well as the collection and storage of study data and personal data of the patient.